3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
23
Thoracic
5
Head & Neck
4
Gynecologic
4
Dermatologic
4
Gastrointestinal
3
Breast
3
Sarcoma
1
Other solid neoplasm
1
Conditions
Sarcoma
39
Leiomyosarcoma
10
Osteosarcoma
8
Breast Neoplasms
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Neuroectodermal Tumors, Primitive, Peripheral
4
Neoplasm Metastasis
4
Melanoma
4
Liposarcoma
4
Histiocytoma, Malignant Fibrous
4
Chondrosarcoma
4
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Sarcoma, Synovial
3
Salivary Gland Neoplasms
3
Prostatic Neoplasms
3
Hemangiosarcoma
3
Esophageal Neoplasms
3
Dermatofibrosarcoma
3
Colorectal Neoplasms
3
Bone Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sarcoma, Kaposi
2
Rhabdomyosarcoma
2
Recurrent Uterine Corpus Sarcoma
2
Neuroblastoma
2
Interventions
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
pembrolizumab
2
Ipilimumab
2
Immunoglobulin G
2
tislelizumab
1
temsirolimus
1
spartalizumab
1
sargramostim
1
regorafenib
1
pemigatinib
1
eribulin
1
cabozantinib
1
brivanib
1
avelumab
1
X-Rays
1
Valproic Acid
1
Sirolimus
1
Radiosurgery
1
Mifepristone
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Docetaxel
1
Disulfides
1
Cyclophosphamide
1
Cryosurgery
1
Colony-Stimulating Factors
1
Clinical Trials, Phase II as Topic
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Docetaxel
×
Sarcoma
×
Clear all
NCT04140526
2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2
Active not recruiting
733 enrolled